| 210 | |
| Search CDDW Abstracts | |
KNOWLEDGE, SYMPTOM SEVERITY AND QUALITY OF LIFE (QOL) OF INTERNET AND TERTIARY-CARE DYSPEPSIA AND GERD PATIENT POPULATIONS
R
Cawdron, D Armstrong
Division
of Gastroenterology, McMaster University, Hamilton, Ontario
BACKGROUND:
Internet-based educational resources may aid dyspepsia patients but significant
differences between tertiary-care and internet respondents with respect to socio-economic
and motivational factors may limit the success of on-line educational resources,
and the viability of on-line research.
AIM: To compare clinic and internet populations' QoL, symptom
severity and knowledge of their dyspepsia or GERD.
METHODS: Gastroenterology clinic patients and internet respondents
with features of GERD, peptic ulcer, non-ulcer dyspepsia, H. pylori
or gallstones completed a survey containing; the Dyspepsia & GERD Knowledge
Questionnaire (DGKQ), the Gastrointestinal Symptom Rating Scale, SF-12, and
items regarding the use of patient education resources. Data were analysed using
ANOVA.
RESULTS: Overall, 84 clinic and 66 internet respondents completed
the surveys. Internet respondents were significantly younger and 30% more had
post-secondary education (PSE) compared to clinic patients, but they had similar
knowledge, symptom and QoL scores. This pattern held for females upon subgroup
analysis, but male internet respondents scored higher on the DGKQ and symptom
surveys despite similar QoL scores and proportions with PSE. (* p < 0.05,
p < 0.001, °p = 0.056)
![]() |
SUMMARY: Internet-based questionnaires are feasible for assessing GERD and dyspepsia patient characteristics. Internet and clinic respondents have a lower QoL than the general population. Despite demographic differences, female clinic and internet respondents had comparable levels of knowledge, QoL and symptom severity. However, male clinic respondents were less knowledgeable than their Internet counterparts. Male tertiary-care GERD and dyspepsia clinic patients may benefit most from patient education initiatives.
Funded by CDHF/AstraZeneca Canada.
NEXT ABSTRACT